Latest news with #Niraparib
Medscape
24-06-2025
- Health
- Medscape
Prostate Cancer Highlights From ASCO 2025
Key findings on prostate cancer treatment from the 2025 ASCO meeting are reported by Dr Oliver Sartor from Tulane Medical School in New Orleans. Dr Sartor begins by highlighting the phase 3 AMPLITUDE trial, which evaluated niraparib (NIRA) combined with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-sensitive prostate cancer. The risk for radiographic progression or death was reduced by 37% using the combination of NIRA plus AAP compared with placebo plus AAP. Next, Dr Sartor discusses a phase 1/2 study of terbium-161, a novel radionuclide that may improve the targeting of micrometastases. The radioligand therapy displayed highly encouraging efficacy and few grade 3 or 4 adverse events. An additional cohort to assess a higher administered radioactivity is planned. Dr Sartor also reports results from a phase 2 trial looking at baseline prognostic value of PSMA-PET total tumor volume (TTV) and PSMA-PET standardized uptake value (SUV) in the ENZA-p trial of enzalutamide (ENZA) vs enzalutamide plus [177Lu] Lu-PSMA-617 (LuPSMA). Baseline PSMA-TTV was prognostic of shorter overall survival for ENZA alone but not for ENZA plus LuPSMA. Individuals with the lower PSMA-PET uptake did much better with enzalutamide than those with a high PSMA-PET uptake. Finally, Dr Sartor examines early data on KLK2 as a novel target amenable to T-cell redirection. The data will be reviewed further in larger, phase 3 studies.
Medscape
06-06-2025
- Health
- Medscape
ASCO 2025: Key Highlights in Prostate Cancer
Dr Petros Grivas surveys several exciting developments in prostate cancer research, including AI-driven biomarker analysis from the STAMPEDE trial, to identify high-risk patients who may benefit from abiraterone. He also discusses positive results from the AMPLITUDE trial, where adding niraparib to standard therapy improved radiographic progression-free survival, especially in patients with BRCA1 or BRCA2 mutations, reinforcing the need for comprehensive genomic testing. Emerging treatments such as bispecific antibodies and radioligand theranostics, including the impact of lutetium-PSMA and updates from the PSMAddition study, showed promise, though practice-changing data are still forthcoming. He emphasizes the importance of leveraging technology and community collaboration to drive progress and improve outcomes in cancer care.
